17.64 USD
+1.16 (+7.04%)
17.64 USD
0 (0%)
Overall GLUE gets a fundamental rating of 5 out of 10. We evaluated GLUE against 530 industry peers in the Biotechnology industry. GLUE has an excellent financial health rating, but there are some minor concerns on its profitability. GLUE has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year GLUE was profitable.
GLUE had a positive operating cash flow in the past year.
In the past 5 years GLUE always reported negative net income.
GLUE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
GLUE has a Return On Assets of 4.56%. This is amongst the best in the industry. GLUE outperforms 90.75% of its industry peers.
GLUE has a better Return On Equity (8.52%) than 91.89% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.69%, GLUE belongs to the top of the industry, outperforming 89.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROIC | 1.69% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 11.54%, GLUE belongs to the top of the industry, outperforming 91.51% of the companies in the same industry.
The Operating Margin of GLUE (4.69%) is better than 89.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GLUE is destroying value.
The number of shares outstanding for GLUE has been increased compared to 1 year ago.
The number of shares outstanding for GLUE has been increased compared to 5 years ago.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 3.25 indicates that GLUE is not in any danger for bankruptcy at the moment.
GLUE has a better Altman-Z score (3.25) than 68.30% of its industry peers.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.25 |
ROIC/WACC0.19
WACC8.79%
2.3 Liquidity
GLUE has a Current Ratio of 6.54. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.54, GLUE is doing good in the industry, outperforming 66.98% of the companies in the same industry.
A Quick Ratio of 6.54 indicates that GLUE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.54, GLUE is doing good in the industry, outperforming 67.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 |
3. Growth
3.1 Past
GLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.94%, which is quite impressive.
Looking at the last year, GLUE shows a very strong growth in Revenue. The Revenue has grown by 1112.27%.
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
3.2 Future
Based on estimates for the next years, GLUE will show a decrease in Earnings Per Share. The EPS will decrease by -8.93% on average per year.
Based on estimates for the next years, GLUE will show a very strong growth in Revenue. The Revenue will grow by 22.64% on average per year.
EPS Next Y71.45%
EPS Next 2Y-22.42%
EPS Next 3Y-13.55%
EPS Next 5Y-8.93%
Revenue Next Year424.57%
Revenue Next 2Y41.6%
Revenue Next 3Y36.35%
Revenue Next 5Y22.64%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 56.90, which means the current valuation is very expensive for GLUE.
Compared to the rest of the industry, the Price/Earnings ratio of GLUE indicates a rather cheap valuation: GLUE is cheaper than 90.57% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.59. GLUE is valued rather expensively when compared to this.
GLUE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.9 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GLUE indicates a rather cheap valuation: GLUE is cheaper than 92.26% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, GLUE is valued cheaper than 98.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.92 | ||
| EV/EBITDA | 34.12 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GLUE's earnings are expected to decrease with -13.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.8
PEG (5Y)N/A
EPS Next 2Y-22.42%
EPS Next 3Y-13.55%
5. Dividend
5.1 Amount
No dividends for GLUE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.64
+1.16 (+7.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.52%
Inst Owner Change7.39%
Ins Owners0.81%
Ins Owner Change0%
Market Cap1.15B
Revenue(TTM)181.54M
Net Income(TTM)20.95M
Analysts84
Price Target17.78 (0.79%)
Short Float %10.85%
Short Ratio6.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.53%
Min EPS beat(2)13.2%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)354.59%
Min EPS beat(4)13.2%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)177.66%
EPS beat(12)11
Avg EPS beat(12)119.51%
EPS beat(16)13
Avg EPS beat(16)84.82%
Revenue beat(2)2
Avg Revenue beat(2)120.76%
Min Revenue beat(2)110.55%
Max Revenue beat(2)130.97%
Revenue beat(4)4
Avg Revenue beat(4)277.19%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)6
Avg Revenue beat(8)183.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.27%
PT rev (3m)7.02%
EPS NQ rev (1m)2.11%
EPS NQ rev (3m)-37.58%
EPS NY rev (1m)10.67%
EPS NY rev (3m)-34.31%
Revenue NQ rev (1m)0.93%
Revenue NQ rev (3m)-16.26%
Revenue NY rev (1m)8.74%
Revenue NY rev (3m)-1.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.9 | ||
| Fwd PE | N/A | ||
| P/S | 6.33 | ||
| P/FCF | 7.92 | ||
| P/OCF | 7.7 | ||
| P/B | 4.67 | ||
| P/tB | 4.67 | ||
| EV/EBITDA | 34.12 |
EPS(TTM)0.31
EY1.76%
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)2.23
FCFY12.62%
OCF(TTM)2.29
OCFY12.98%
SpS2.79
BVpS3.78
TBVpS3.78
PEG (NY)0.8
PEG (5Y)N/A
Graham Number5.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROCE | 2.14% | ||
| ROIC | 1.69% | ||
| ROICexc | 94.17% | ||
| ROICexgc | 94.17% | ||
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A | ||
| FCFM | 79.89% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.42% | ||
| Cap/Sales | 2.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 885.62% | ||
| Profit Quality | 692.36% | ||
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 | ||
| Altman-Z | 3.25 |
F-Score8
WACC8.79%
ROIC/WACC0.19
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
EPS Next Y71.45%
EPS Next 2Y-22.42%
EPS Next 3Y-13.55%
EPS Next 5Y-8.93%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
Revenue Next Year424.57%
Revenue Next 2Y41.6%
Revenue Next 3Y36.35%
Revenue Next 5Y22.64%
EBIT growth 1Y106.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.16%
EBIT Next 3Y42.19%
EBIT Next 5YN/A
FCF growth 1Y218.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.12%
OCF growth 3YN/A
OCF growth 5YN/A
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GLUE.
Can you provide the valuation status for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Fairly Valued.
What is the profitability of GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.
What is the earnings growth outlook for MONTE ROSA THERAPEUTICS INC?
The Earnings per Share (EPS) of MONTE ROSA THERAPEUTICS INC (GLUE) is expected to grow by 71.45% in the next year.